Fresh Tracks Therapeutics, Inc.

OTCPK:FRTX Stock Report

Market Cap: US$4.2m

Fresh Tracks Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Bert Marchio

Chief executive officer

US$254.8k

Total compensation

CEO salary percentagen/a
CEO tenure4.1yrs
CEO ownershipn/a
Management average tenure3.3yrs
Board average tenure3yrs

Recent management updates

Recent updates

Brickell Biotech changes name to Fresh Tracks Therapeutics

Sep 07

Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M

Aug 11

Brickell Biotech regains Nasdaq compliance for minimum bid price requirement

Jul 20

Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely

Feb 14
Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely

Brickell Biotech Advances To Phase III As It Eyes Commercialization

May 10

Brickell Biotech completes patient enrollment in late-stage sweat disorder study

Apr 27

Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.

Jan 06
Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.

Brickell Biotech (BBI) Investor Presentation - Slideshow

Dec 02

Brickell Bio to launch sofpironium bromide gel, 5% in Japan on November 26

Nov 18

CEO

Bert Marchio (72 yo)

4.1yrs

Tenure

US$254,834

Compensation

Mr. Albert Nicholas Marchio, II, also known as Bert, was Interim CFO & Principal Accounting Officer of NexImmune, Inc. from April 16, 2024 to August 27, 2024. He serves as Chief Financial Officer at Fresh...

Leadership Team

NamePositionTenureCompensationOwnership
Albert Marchio
CEO, CFO4.1yrsUS$254.83kno data
Aron Aizenstat
Vice President of Corporate Development & Operationsno datano datano data
Aaron Fox-Collis
VP of Finance & Chief Accounting Officer2yrsno datano data
Sue Fattor
Head of Human Resource3.8yrsno datano data
James McElvain
Interim Head of CMC Development2.8yrsno datano data

3.3yrs

Average Tenure

Experienced Management: FRTX's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Albert Marchio
CEO, CFO1.3yrsUS$254.83kno data
Katherine Fitzgerald
Member of Scientific Advisory Board3yrsno datano data
Peter Nigrovic
Member of Scientific Advisory Board3yrsno datano data
Pui Lee
Member of Scientific Advisory Board3yrsno datano data
Bernard Khor
Member of Scientific Advisory Board3yrsno datano data
Bridget Wagner
Member of Scientific Advisory Board3yrsno datano data

3.0yrs

Average Tenure

Experienced Board: FRTX's board of directors are considered experienced (3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/11 21:08
End of Day Share Price 2025/01/08 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Fresh Tracks Therapeutics, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuH.C. Wainwright & Co.
Thomas FlatenLake Street Capital Markets, LLC
Leland GershellOppenheimer & Co. Inc.